Skip to main content

Celcuity

Celcuity Inc is an American clinical-stage biotechnology enterprise developing targeted oncology therapeutics and cellular diagnostic platforms for cancer treatment. The company advances gedatolisib, a pan-PI3K/mTOR inhibitor in pivotal Phase 3 clinical trials for HR+/HER2- advanced breast cancer and prostate cancer, alongside developing the CELsignia diagnostic platform to measure live cell signaling pathways. Principal revenue is driven through research milestone payments, strategic development partnerships, and capital raises prior to commercial authorization. Core end markets serve medical oncology centers, breast cancer clinical research institutes, and targeted prescription cancer patients globally. Celcuity holds an innovative position in the biopharmaceutical sector as a developer of dual PI3K/mTOR targeted cancer therapies and live-cell signaling diagnostics. The corporation is headquartered in Minneapolis, Minnesota, and its common stock trades on the Nasdaq Capital Market.

4 of the funds FundTelligence covers report a position in Celcuity.

Legal name
Celcuity Inc
Sector
Health Care
Country
United States
Funds holding it
4
Exposure themes
Cancer, Treatment, Women's Health

Funds holding Celcuity

Loading...